DBV Technologies S.A. (NASDAQ:DBVT) Receives $38.65 Average Price Target from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have earned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $38.65.

A number of brokerages have commented on DBVT. Citizens Jmp lifted their target price on shares of DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a research note on Friday, March 27th. Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a research note on Wednesday, December 17th. Guggenheim restated a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a report on Friday, March 27th. HC Wainwright set a $40.00 price target on shares of DBV Technologies in a research report on Thursday, December 18th. Finally, Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th.

Hedge Funds Weigh In On DBV Technologies

Several large investors have recently modified their holdings of DBVT. Ikarian Capital LLC purchased a new position in shares of DBV Technologies during the 4th quarter worth $10,064,000. Vestal Point Capital LP acquired a new stake in shares of DBV Technologies during the 4th quarter worth about $5,751,000. Squadron Capital Management LLC purchased a new stake in DBV Technologies in the 4th quarter valued at about $4,601,000. Millennium Management LLC raised its holdings in DBV Technologies by 89.7% in the 4th quarter. Millennium Management LLC now owns 640,885 shares of the company’s stock valued at $12,286,000 after buying an additional 303,022 shares during the period. Finally, Engineers Gate Manager LP acquired a new position in DBV Technologies in the fourth quarter valued at about $479,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Stock Up 6.8%

Shares of DBVT opened at $20.89 on Friday. DBV Technologies has a 52-week low of $5.75 and a 52-week high of $26.18. The company has a market capitalization of $1.16 billion, a PE ratio of -4.00 and a beta of -0.97. The stock has a fifty day simple moving average of $21.56 and a two-hundred day simple moving average of $17.48.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($1.15) EPS for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%.The company had revenue of $0.65 million for the quarter. As a group, equities analysts anticipate that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.